Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist, for the ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...